Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...
Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...
Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results